Phaseline

Targets › ADORA2A

ADORA2A (Adenosine receptor A2a): drug programs, companies and trials

40 programs from 39 companies in 65 trials: 28 Phase 2, 15 Phase 1, 14 Phase 4, 8 Phase 3; Other, Oncology, Cardiovascular; next expected readout Dec 2026.

Receptor for adenosine (By similarity). The activity of this receptor is mediated by G proteins which activate adenylyl cyclase (By similarity). (UniProt, P29274)

Open in Phaseline: the race on ADORA2A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
St Joseph University, Beirut, LebanonPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 4Lumbar RadiculopathyDec 2026
Region SkaneAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Chronic Coronary SyndromeDec 2026
National Institute of Cardiovascular Diseases, PakistanAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4ST-Segment Elevation Myocardial Infarction (STEMI)Dec 2026
University of Alabama at BirminghamCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Premature Infant DiseaseMay 2027
Anne E. Zepeskiadenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Supraventricular Tachycardia (SVT)Jul 2027
Semmelweis UniversityCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Apnea of PrematurityDec 2027
Weill Medical College of Cornell UniversityAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Premature Ventricular Contraction (PVC)Dec 2027
VA Office of Research and DevelopmentPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 4Diabetic Kidney DiseaseJan 2028
Vastra Gotaland RegionAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Takotsubo SyndromeDec 2028
RDC ClinicalCaffeine
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Exercise; Migraine; Healthy; Vibration Therapy …–
Al-Azhar UniversityPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3Chronic Kidney DiseasesDec 2026
Arcus Biosciencescasdatifan
Adenosine A2A receptor antagonist
ADORA2APhase 3Metastatic Clear Cell Renal Cell Carcinoma; Healthy Participants; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma …May 2027
Tanta UniversityPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3IBS - Irritable Bowel Syndrome; Rheumatoid ArthritisMay 2027
NICHD Global Network for Women's and Children's HealthCaffeine Citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 3Hypoxic Ischemic Encephalopathy (HIE)Dec 2029
Rashid Latif Medical CollegeAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 3Supraventricular Tachycardia (SVtach)–
University of WashingtonPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3Medication-related Osteonecrosis of the Jaw–
Beni-Suef Universitypentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3Embryo Transfer–
New York Medical CollegeDefibrotide
Adenosine A2 receptor agonist; Plasminogen activator; Adenosine A1 receptor agonist
ADORA2B, ADORA2A, PLG, ADORA1, F2Phase 2Sickle Cell Disease; Sinusoidal Obstruction SyndromeDec 2026
Mostafa BahaaPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2EpilepsyDec 2026
Ihab Elsayed HassanPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Inflammatory Bowel DiseasesJan 2027
University Hospital, LimogesPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Medication-related Osteonecrosis of the Jaw (MRONJ)Apr 2027
Zhejiang Vimgreen PharmaceuticalsVG081821AC
Adenosine A2A receptor antagonist
ADORA2APhase 2Parkinson Disease (PD)Oct 2027
Ministry of Health, Saudi ArabiaCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 2PrematurityOct 2027
University of RochesterCaffeine Citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 2Neonatal ApneaJul 2028
TJ BiopharmaUliledlimab
CD73 inhibitor
ADORA2APhase 2Non Small Cell Lung CancerAug 2028
M.D. Anderson Cancer CenterPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Lymphedema; Fibrosis SyndromeMay 2029
Gilead SciencesEtrumadenant
Adenosine A2a receptor antagonist; Adenosine A2b receptor antagonist
ADORA2A, ADORA2BPhase 2Lung Cancer; Oligometastatic Prostate Cancer; Rectal Cancer; Pancreatic Ductal Adenocarcinoma …Sep 2029
University of Wisconsin, MadisonCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 2Kidney InjuryMar 2030
University Health Network, TorontoPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Non-Small Cell Lung CancerNov 2031
iTeos TherapeuticsInupadenant (EOS100850)
Adenosine 2A receptor antagonist
ADORA2APhase 2Metastatic NSCLC - Non-Small Cell Lung Cancer–
GE HealthcareRegadenoson
Adenosine A2a receptor agonist
ADORA2APhase 1Myocardial Ischemia; Heart Transplant Failure and Rejection; Sickle Cell DiseaseDec 2026
Indiana UniversityCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 1Preterm Labor With Preterm DeliveryJun 2027
University of ChicagoCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 1Enhanced Recovery After Surgery in a Pediatric PopulationDec 2027
University of North Carolina, Chapel HillCaffeine Citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 1Hypoxic-Ischemic EncephalopathyJul 2028
M.D. Anderson Cancer CenterCiforadenant
Adenosine A2a receptor antagonist
ADORA2APhase 1Renal Cell CarcinomaNov 2028
McMaster UniversityAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 1Chronic Cough (CC)–
Nishtar Medical UniversityCaffeine Citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 1Apnea of Prematurity–
Innolake BiopharmILB2109
A2a receptor antagonist
ADORA2APhase 1Advanced Solid Tumor–
AstraZenecaImaradenant (AZD4635)
Adenosine A2a receptor antagonist
ADORA2APhase 1Carcinoma, Non-Small-Cell Lung–
University of Floridaistradefylline
Adenosine A2a receptor antagonist
ADORA2APhase 1ALS–

Conditions

Apnea of Prematurity (3) Non Small Cell Lung Cancer (3) Renal Cell Carcinoma (2) Sickle Cell Disease (2) Hypoxic-Ischemic Encephalopathy (2) Metastatic Clear Cell Renal Cell Carcinoma (1) Healthy Participants (1) Clear Cell Renal Cell Carcinoma (1) Refractory Clear Cell Renal Cell Carcinoma (1) Supraventricular Tachycardia (SVT) (1) Medication-related Osteonecrosis of the Jaw (1) Medication-related Osteonecrosis of the Jaw (MRONJ) (1)

Modalities

small molecule (34), mixed (3), antibody (1), protein or peptide (1)

Companies

M.D. Anderson Cancer Center (2) Arcus Biosciences (1) Anne E. Zepeski (1) University of Washington (1) University Hospital, Limoges (1) Semmelweis University (1) University of Alabama at Birmingham (1) TJ Biopharma (1) New York Medical College (1) Gilead Sciences (1) RDC Clinical (1) Mostafa Bahaa (1) Weill Medical College of Cornell University (1) Zhejiang Vimgreen Pharmaceuticals (1) Vastra Gotaland Region (1) University of Chicago (1) McMaster University (1) VA Office of Research and Development (1) University of Florida (1) iTeos Therapeutics (1)

Related targets

ADORA2B (31) ADORA1 (19) ADORA3 (18) PDE5A (11) PDE4A (11) PDE3A (11) PLG (1) F2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.